Wealthfront Advisers LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA)

Wealthfront Advisers LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 84.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,013 shares of the company's stock after selling 10,898 shares during the quarter. Wealthfront Advisers LLC's holdings in Moderna were worth $84,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Knuff & Co LLC grew its position in Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock valued at $316,000 after acquiring an additional 244 shares during the last quarter. Allworth Financial LP grew its position in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares during the last quarter. Howard Capital Management Inc. grew its position in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after acquiring an additional 297 shares during the last quarter. Larson Financial Group LLC grew its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after acquiring an additional 317 shares during the last quarter. Finally, Empowered Funds LLC grew its position in Moderna by 6.6% during the third quarter. Empowered Funds LLC now owns 5,199 shares of the company's stock valued at $347,000 after acquiring an additional 322 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Moderna Trading Up 0.6 %

Moderna stock traded up $0.21 on Friday, hitting $32.66. 9,309,839 shares of the stock traded hands, compared to its average volume of 6,595,124. The firm has a market cap of $12.60 billion, a P/E ratio of -3.52 and a beta of 1.86. The business's fifty day simple moving average is $35.10 and its 200 day simple moving average is $46.36. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target on the stock. Berenberg Bank increased their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Argus cut shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. cut their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Friday. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and a consensus price target of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.